Replies to post #105413 on Biotech Values

[zipjet]

Teva tried to include additional patents in the case against NVS/MNTA that have a later expiration date, but the Judge refused to allow those patents to be admitted. Unless this ruling by the District Court is overturned on appeal, NVS/MNTA do not have to be concerned with any US Copaxone patents that run beyond May 24, 2014.

Does that conclusion flow from a statute? Does it flow from the law of joinder? Does it flow from cases on patent law? Whence cometh? :-)

I understand the statement but not where it comes from.

ij